Cargando…
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
Minimal residual disease (MRD) detection represents a sensitive tool to appropriately measure the response obtained with therapies for multiple myeloma (MM). The achievement of MRD negativity has superseded the conventional complete response (CR) and has been proposed as a surrogate endpoint for pro...
Autores principales: | Mina, Roberto, Oliva, Stefania, Boccadoro, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408660/ https://www.ncbi.nlm.nih.gov/pubmed/32645952 http://dx.doi.org/10.3390/jcm9072142 |
Ejemplares similares
-
Erratum: Mina, R.; et al. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. J. Clin. Med. 2020, 9, 2142
por: Mina, Roberto, et al.
Publicado: (2020) -
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020) -
Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020) -
Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023) -
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT
por: Lecouvet, Frederic E., et al.
Publicado: (2021)